Donate Toggle Menu

2023 IKCS: Europe

21-22 April, 2023

Edinburgh International Conference Centre
Edinburgh, Scotland, UK

Registration, Hotel, and Abstract Submission are Now Open!

Important Dates

Review the important dates below for 2023 IKCS: Europe

Abstract Submissions OpenDecember 2022
Program-At-A-GlanceJanuary 2023
Registration Now OpenDecember 2022
Hotel Reservation InformationDecember 2022
Program Details and Speakers ReleasedJanuary 2023
Abstract Submission Deadline
(all complete Regular, TPS, and Case Report submissions, and all LBA Placeholders due at this time)
31 January 2023 at 23:59 PST
LBA Submission Deadline (LBA Placeholder required by August 2 deadline)22 February 2023 at 12:00 (Noon) PST (placeholder required by 31 January)
Abstract Notifications Sent to Lead AuthorsMid-February 2023
Early Symposium Registration Deadline8 March 2023 at 23:59 PST
Abstract Withdrawal Deadline
(Withdrawal requests must be submitted by the Lead Author to [email protected])
8 March 2023 at 23:59 PST
Abstract Titles ReleasedMid-March 2023
Deadline to cancel Hotel Reservations without feesTBD
Presentation Slides Due23 March 2023
Poster Uploads Due5 April 2023
Abstracts Released 17 April 2023 at 16:00 BST
Post-Meeting On Demand AvailableBeginning of May 2023
Meeting Dates21-22 April 2023

Registration and Hotel Information


CategoryEarly Registration Rate (Register by March 23, 2023 at 23:59 GMT)Regular Registration Rate (After March 23, 2023)Post-Event (April 25, 2023 to December 31, 2023)
In-person Physician/Scientist£335£445N/A
Group In-person Physician/Scientist (this rate includes 1 in-person Physician/Scientist registration and 3 post-meeting on-demand access registrations)£550£700N/A
In-person Allied Health Professional£232£325N/A
In-person Physician In-Training£235£325N/A
In-person Patient/Advocate/CaregiverComplimentary*£75N/A
In-person Industry£445£585N/A
In-person MediaComplimentary**Complimentary**N/A
Post-Event On-Demand Access£315£315£315
*If you are a Patient, Advocate, or Caregiver please contact [email protected] with your interest in attending IKCS. This Registration category is reserved for Patients, Advocates, and Caregivers who do not meet one of the other registration categories.

**If you are a Media employee interested in attending IKCS, please contact [email protected] with your interest and plan for meeting coverage. This Registration category is reserved only for Media.

Hotel Accommodations

Meeting Venue: Edinburgh International Conference Centre
Venue Address: The Exchange, 150 Morrison St, Edinburgh EH3 8EE, United Kingdom




Abstract Submissions are open now!

Abstract Submission Guidelines

Abstract Submission Guidelines

Follow the guidelines below to submit an abstract to IKCS: Europe.

  • All submitters are required to create a free account with Cadmium to access the abstract submitter.
  • Important Deadlines
  • Abstract Submission Deadline (all submissions including LBA placeholder submissions due at this time): 31 JANUARY 2023 AT 23:59 PDT
  • LBA Final Data Submission Deadline (final data, results, and conclusions for LBA placeholder submissions due at this time): 22 FEBRUARY 2023 at 12:00 (Noon) PDT
  • Additional instructions will be sent to lead authors to complete their LBA submissions
  • Abstract Notifications will be sent to lead authors in Mid-February 2023.
  • LBA lead authors will receive abstract notifications in Late February 2023.

Abstract Submission Types:

  • Regular Abstract (All research types and summaries of new, ongoing, and updated research relating to kidney cancer will be considered)
  • Trials in Progress Abstract (All research types that are open, enrolling, ongoing, and have not reached pre-specified endpoints for analysis.)
  • Late-breaking Data Submission Abstract (Phase I, II, III, or IV trials and original, high-impact research that could impact practice and standard of care)
  • Case Report (A report of the diagnosis, treatment, and follow up of an individual patient)

Abstract Sections:

  • Abstract Title: The title should objectively describe the study and should not include proprietary drug names.
  • Abstract Text: The abstract text should be no more than 300 words including the title and abstract body. Word count does not apply towards spaces, authors, and affiliations. All abstracts should be structured into four sections: Background, Methods, Results, Conclusions
  • Optional Abstract Graph, Illustration, or Table: One brief graph, illustration, or table is permitted.
  • Authors: The maximum number of authors permitted is 20.
  • Pharmaceutical industry authors are allowed to present abstracts in non-CME sessions (Poster Sessions). If an abstract is selected for presentation in a CME-session, and the presenter has financial relationships with ACCME-defined ineligible companies, an alternate presenter must be identified. A non-named author can present a poster if written permission is provided by the lead author to [email protected].
  • Conflict of Interest Disclosure: Presenting authors must submit a Conflict of Interest disclosure identifying financial relationships with ACCME-defined ineligible companies. Co-authors do not need to submit a COI Disclosure.

Abstract Policies:

  • Confidentiality Policy: Abstracts are confidential at the time of submission. KCA will release full abstracts on the meeting platform website 17 April 2023 at 16:00 BST leading up to the meeting. Meeting registration is required to access the abstracts.
  • Abstract Presentation Ownership: Abstract Presentations (PPT slides and Posters) are owned by the author.
Abstract Submission Categories

Abstract Submission Categories

Abstracts in the following categories will be considered for presentation:

  • Basic Science
  • Disparities in Cancer, Care and Access
  • Diagnostics
  • Financial Toxicity – Care Delivery/Health Outcomes
  • Imaging
  • Patient-reported Outcomes
  • Post-treatment Surveillance
  • Prevention and Screening
  • Quality of Care and Quality Improvement
  • Real-World Evidence
  • Survivorship
  • Treatment Toxicities and Symptom Management
  • Therapeutics (Systemic- Radiation Therapy, Ablation, Surgery, Interventional Radiology, Urology, Medical Oncology, etc.)
  • Therapeutics (Local- Primary and Metastatis)
  • Tumor Biology, Biomarkers, and Pathology
  • Other
Late-breaking Data Submission Guidelines

Abstracts submitted in this category are Phase I-IV trials, or original research that could impact practice and standard of care. LBA Abstracts should be studies where results and conclusions are not yet available by the 31 January deadline, but will be available by the 22 February 12:00 (Noon) PST deadline.

Abstracts submitted in this category must have a placeholder submission (all components except for Results and Conclusions sections) received by the 31 January 2023 23:59 PST abstract submission deadline.

Lead authors will receive separate instructions to complete LBA placeholder submissions by the 22 February LBA deadline.

Submit an Abstract Here

Trials in Progress Abstract Submission Guidelines

Abstracts submitted in this category are ongoing and should not include data, results, nor conclusions.

TPS abstracts are open, enrolling, or ongoing and have not reached any protocol-specific endpoints for analysis, and consequently will only require the completion of the Background and Methods sections.

Abstracts in all phases of clinical research (I, II, III, IV) may be submitted.

TPS Abstracts, if accepted, are eligible for Poster Presentation. TPS abstracts are not eligible for Oral Presentation.

Submit an Abstract Here

Abstract Review and Selection Process

Abstract Review and Selection Process

Abstracts will be reviewed by the IKCS: Europe Scientific Planning Committee. Abstract notifications will be sent to lead authors in February 2023.

Abstract-Associated Awards: New for 2022

IKCS: Europe Merit Awards

Merit Awards are given to early-career abstract authors within 5 years of completing residency of high-quality submitted abstracts. To apply for a Merit Award, the presenting author should select “Yes” to the question “would you like to apply for a merit award?” The presenting author is required to upload a CV/Resume and a Letter of Support from their training program supervisor substantiating the applicant’s good standing in their training program.

Merit Award Eligibility Requirements:

  • Must have a doctorate-level advanced degree (MBBS, MD, PhD, PharmD, etc.) in-progress or completed at the time of submission. Applicants may also be PhD candidates, as well as individuals within 5 years of completing residency.
  • Must be enrolled and in good standing in an oncology or urology training program, residency, or post-doctoral researcher position
  • Must upload a CV/Resume and Letter of Support showing participation and good standing in training program

The IKCS Scientific Planning Committee will select recipients to receive a merit award for the best original submissions.
*Please note: Trials in Progress presentations will not be eligible to receive a merit award.

  • First place: £425 and complimentary meeting registration
  • Second place: £215 and complimentary meeting registration
  • Third place: £85 and complimentary meeting registration
Abstract Presenter Guidelines (Oral & Poster Presentation Guidelines)

Abstract Presenter Guidelines

All accepted abstracts and lead authors are requested to present in-person at IKCS: Europe. Accepted abstracts will be displayed at the live meeting and electronic versions will be available online for post-meeting on-demand access.

All Abstract Presenters must register for the conference.

Oral Abstract Presenter Guidelines

  • Presentation Format: Oral Abstract Presenters should prepare a 7-minute PPT presentation
  • Slide Upload Deadline: PPT slides are due in the presenter portal by March 22, 2023. We will try our best to process late files, however, files received after this date cannot be guaranteed inclusion in the conference platform.
  • Conflict of Interest Disclosure: Oral Abstract Presentations must include in a COI Disclosure slide
  • Withdrawal Deadline: All withdrawal requests must be sent in writing from the first author to [email protected] by March 8, 2023. Requests received after this date cannot be guaranteed removal from the program.
  • Corresponding Poster: Oral Abstract presenters should also prepare a poster presentation to accompany their oral presentation.

Poster Presenter Guidelines

  • Poster Presenters should prepare a PDF and printed poster. Attendees will have the opportunity to visit posters in-person onsite and view electronic versions online.
  • ePoster Deadline: Presenters should upload a PDF poster to the Speaker Portal by March 31, 2023. We will try our best to process late files, however, files received after this date cannot be guaranteed inclusion in the conference platform.
  • Printed Posters: Poster Presenters should bring a printed poster onsite to hang on an assigned poster board for the duration of the meeting.
  • Size: Printed posters should not exceed 1 Meter by 1 Meter. This is the size of the Poster Board. Poster hanging materials will be provided onsite.
  • Printing: Poster Presenters should arrange their own poster printing and carry their poster onsite. If a Poster Presenter is unable to attend in-person, they should arrange for a colleague to carry and present the poster onsite.
  • KCA is not responsible for costs associated with printing and shipping posters.
  • Template: No specific Poster Template is required.
  • Withdrawal Deadline: All withdrawal requests must be sent in writing from the first author to [email protected] by March 8, 2023. Requests received after this date cannot be guaranteed removal from the program.
Abstract Release Information

Abstract texts will be released on the hybrid meeting platform on 17 April 2023 at 16:00 BST.

Poster Presentations will become available beginning 21 April 2023. PDF versions of presentation slides will become available during the specific session for the presentation.

Submit an Abstract Here


Please contact [email protected].

Continuing Medical Education (CME) Information

Jointly provided by The France Foundation and the Kidney Cancer Association.

Target Audience: This educational activity is intended for medical oncologists and urologists who treat patients with kidney cancer. Fellows, trainees, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of kidney cancer are invited to participate.

Statement of Need: Education and interaction surrounding the space of renal cell carcinoma are paramount to improving patient care. This program is targeted to physicians, advocates, researchers, and care team members to help promote learning and collaboration for advancement in the renal cancer space.

Educational Learning Activity Objectives: Upon completion of this course, the participants should be able to:

Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the Kidney Cancer Association. The France Foundation is accredited by ACCME to provide continuing medical education for physicians.

Credit Designation:

Physicians: The France Foundation designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The 2022 IKCS: Europe – International Kidney Cancer Symposium, Antwerp, Belgium, 22/04/2022- 24/04/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 14 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama–assn.org/education/earn–credit–participation–international–activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

IKCS: Europe Scientific Planning Committee

Thank you to our 2023 IKCS: Europe Planners!

Ignacio Duran, MD, PhD
Annika Fendler
Lars Lund, MD, DMSci
Gabriel Malouf, MD, PhD
Lisa Pickering, MD, PhD
Michael Staehler, MD, PhD
Cristina Suarez, MD, PhD

2023 IKCS: Europe Planning Committee disclosures will be available here in January 2023.

Faculty Presentation Guidelines

Speaker PPT Slide Presentations are due in the Faculty/Speaker Portal by 22 March, 2023.

Meeting Format

Meeting Format: 2023 IKCS: Europe will be a live event offering in-person participation for meeting attendees. On-demand Virtual access will be available post-meeting. Sessions will be recorded, but will not be live-streamed. Faculty are expected to attend in-person in, however, reasonable adjustments may be considered due to COVID-19 related travel restrictions.

Conflict of Interest Disclosure & Session Preparation Information

Conflict of Interest Disclosure: Confirmation of any faculty invitation requires agreement to abide by Conflict of Interest procedures in addition to policies set forth by the Kidney Cancer Association, The France Foundation, and the Accreditation Council for Continuing Medical Education (ACCME) for content and presentation. All Faculty are required to submit a full disclosure of financial interests with commercial entities. All Conflict of Interest Disclosures will be reviewed by The France Foundation for final approval and participation in the program. Failure to submit a Conflict of Interest Disclosure will prohibit participation in the program.

Session Preparation: Speakers should upload their presentation slides by 22 March 2023. Slides will be reviewed by Session Chairs/Moderators and CME regulators to ensure compliance with CME guidelines, minimize content overlap between sessions, and help presentations contribute to a cohesive and educational session. Speakers may receive recommendations for slide adjustments. Speakers who are only able to participate virtually will receive instructions to pre-record their presentations prior to the meeting, along with instructions to participate in the live panel Q+A at the end of the session.

Download the PPT Template– Available January 2023

Faculty Benefits: Faculty may be eligible for benefits including Registration, Hotel accommodation, and travel assistance. Faculty will receive details and instructions for meeting arrangements directly via email. If you have questions please contact [email protected]

Sponsorship and Exhibitor Opportunities

Please contact [email protected] for more information.